Therapeutic effect of epusartan on coronary heart disease complicated hypertension and its influence on mean sitting systolic blood pressure
10.3969/j.issn.1008-0074.2018.01.08
- VernacularTitle:依普沙坦治疗冠心病合并高血压的临床疗效及对坐位收缩压的影响
- Author:
Gen LI
1
;
Wen TIAN
Author Information
1. 中国医科大学第一临床学院
- Keywords:
Coronary disease;
Hypertension;
Blood pressure;
Epusartan
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2018;27(1):25-29
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To study therapeutic effect of epusartan on coronary heart disease (CHD) complicated hypertension and its influence on mean sitting systolic blood pressure (MSSBP). Methods: A total of 218 CHD patients with hypertension treated in our hospital were selected. They were randomly divided into losartan group (n=108, received losartan based on routine treatment) and epusartan group (n=110, received epusartan based on routine treatment), both groups were treated for six months. Levels of blood lipids, aspartate transaminase (AST) and alanine transaminase (ALT), mean sitting diastolic blood pressure (MSDBP), MSSBP, whole blood low shear viscosity (WBLSV), whole blood high shear viscosity (WBHSV), plasma viscosity (PV) and erythrocyte aggregation index (EAI) before and after treatment, therapeutic effect and incidence of adverse reactions were measured and compared between two groups. Results: There were no significant difference in levels of blood lipids, AST and ALT between two groups before and after treatment, and between before and after treatment, P＞0. 05 all. Compared with losartan group after treatment, there were significant reductions in levels of MSSBP [(131. 75±13. 52) mmHg vs. (117. 95±11. 83) mmHg], WBLSV [(10. 98±1. 27) mPa s vs. (10. 21±1. 13) mPa s], WBHSV [(4. 99±0. 52) mPa s vs. (4. 56±0. 45) mPa s], PV [(2. 01±0. 34) mPa s vs. (1. 70±0. 26) mPa s]and EAI [(8. 59±0. 92) ％ vs. (8. 02±0. 83) ％]in epusartan group, P=0. 001 all. Total effective rate of epusartan group was significantly higher than that of losartan group (98. 18％ vs. 86. 11％, P=0. 001). Conclusion: Epusartan can significantly reduce MSSBP, improve hemorheological indexes with significant therapeutic effect in patients with coronary heart disease complicated hypertension, which is worth application in clinic.
